Previous 10 | Next 10 |
home / stock / kaltf / kaltf news
SAN FRANCISCO and TEL AVIV, Israel, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced that the United States Patent and Trademark Office (the “ USPTO ”) has issued a Notice of All...
SAN FRANCISCO and TEL AVIV, Israel, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced that it has not paid the principal (in the amount of C$453,000) and interest (in the amount of C$19,323.96)...
SAN FRANCISCO and TEL AVIV, Israel, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced that, in accordance with the previously announced agreement between the Company and the former shareholders...
SAN FRANCISCO, Calif. and TEL AVIV, Israel, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today reported financial results for the third quarter of 2019. (All dollars U.S. unless otherwise noted.) ...
SAN FRANCISCO and TEL AVIV, Israel, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced that research reported in two peer-reviewed articles published in Blood provide further evidence supporting...
SAN FRANCISCO and TEL AVIV, Israel, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “ Company ” or “ Kalytera ”) is pleased to announce that it has closed an additional and final tranche of its private placem...
SAN FRANCISCO and TEL AVIV, Israel, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the “ Company ” or “ Kalytera ”) is pleased to announce that it has closed an additional tranche of its private placement, for 1...
SAN FRANCISCO AND TEL AVIV, Israel, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") has announced that, due to a decline in the market price for CBD isolate, it has decided not to proceed with its previously...
SAN FRANCISCO and TEL AVIV, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") is pleased to announce that the European Patent Office has issued a Notice of Allowance for EU Patent Application Number 14...
SAN FRANCISCO and TEL AVIV, Israel, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “ Company ” or “ Kalytera ”) is pleased to announce the closing of the first tranche of its private placement, for 10,946,...
News, Short Squeeze, Breakout and More Instantly...
Kalytera Therapeutics Company Name:
KALTF Stock Symbol:
OTCMKTS Market:
Kalytera Therapeutics Website:
SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has received comments from the Australian Human Research Ethics Committee (the “...
SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that the Australian Human Research Ethics Committee (HREC) will meet on February 16 th to...
SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “ Company ” or “ Claritas ”) today announced revised, improved pricing for the initial tranche of funds that the Co...